Related Experiment Video
Updated: Aug 18, 2026
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Experimental study on myocardial protection by adjunct use of carperitide (hANP) in cardiac surgery
1Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan.
Insights
Human atrial natriuretic peptide (hANP) protects the heart during cardiac surgery. This study shows hANP reduces myocardial injury from ischemic reperfusion, offering direct cardiac protection.
Area of Science:
- Cardiology
- Cardiac Surgery
- Biochemistry
Background:
- Human atrial natriuretic peptide (hANP) has known benefits in internal medicine and surgery.
- Direct myocardial protection by hANP against ischemic reperfusion injury is understudied, particularly in cardiac surgery.
Purpose of the Study:
- To investigate the direct myocardial protective effects of hANP against ischemic reperfusion injury during cardiac surgery.
Main Methods:
- Twenty-four pigs underwent cardiopulmonary bypass and were divided into control, low-dose hANP, and high-dose hANP groups.
- Measurements included blood and myocardial cGMP, myocardial Ca and ATP concentrations.
- Histological examination using electron microscopy assessed myocardial injury.
Main Results:
- hANP treatment significantly increased myocardial cGMP and ATP levels.
- hANP treatment significantly decreased myocardial Ca concentrations.
- Electron microscopy revealed minimal ischemic reperfusion injury in hANP-treated groups.
Conclusions:
- hANP demonstrates direct myocardial protection against injury during cardiac surgery.
- hANP improves outcomes related to ischemic reperfusion injury following cardioplegic arrest and cardiopulmonary bypass.
Background:
In recent years, various beneficial roles of human atrial natriuretic peptide (hANP) have been demonstrated in the internal medicine and surgical fields. However, direct myocardial protection by hANP against myocardial ischemic reperfusion injury has been rarely investigated. Thus, we investigated it from aspects of cardiac surgery.
Methods:
Twenty-four pigs underwent extracorporeal circulation and were divided into three groups: control group (treated with only cardioplegic solution after aorta clamping; cardioplegic arrest for 30 minutes followed by reperfusion for 60 minutes); low dose group (treated with cardioplegic solution and ANP (25 microg)); and high dose group (treated with cardioplegic solution and ANP (100 microg)). Blood and myocardial cGMP, myocardial Ca and ATP concentration were determined. Histological examinations were performed using an electron microscope.
Results:
Blood and myocardial cGMP and myocardial ATP levels were significantly higher in the hANP treatment groups than the control group. Myocardial Ca concentrations were significantly lower in the hANP treatment groups than the control group. In electron microscopy, ischemic reperfusion injury was rarely observed in the hANP treatment groups.
Conclusion:
The study demonstrated that hANP improves ischemic reperfusion injury and suggested that hANP exerts direct myocardial protection against myocardial injury associated with cardiac surgery (cardioplegic arrest while cardiopulmonary bypass).
